Basal Cell and Cutaneous Squamous Cell Carcinomas: Diagnosis and Treatment

被引:1
|
作者
Firnhaber, Jonathon M. [1 ]
机构
[1] East Carolina Univ, Brody Sch Med, Greenville, NC 27834 USA
关键词
PRIMARY-CARE; SKIN; MANAGEMENT; RISK;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Keratinocyte carcinoma, traditionally referred to as nonmelanoma skin cancer, includes basal cell and cutaneous squamous cell carcinoma and is the most common skin cancer malignancy found in humans. The U.S. Preventive Services Task Force recommends counseling about minimizing exposure to ultraviolet radiation for people aged six months to 24 years with fair skin types to decrease their risk of skin cancer. Routine screening for skin cancer is controversial. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of a routine whole-body skin examination to screen for skin cancer. Basal cell carcinoma commonly appears as a shiny, pearly papule with a smooth surface, rolled borders, and arborizing telangiectatic surface vessels. Cutaneous squamous cell carcinoma commonly appears as a firm, smooth, or hyperkeratotic papule or plaque, and may have central ulceration. Initial tissue sampling for diagnosis is a shave technique if the lesion is raised, or a punch biopsy of the most abnormal-appearing area of skin. High-risk factors for recurrence and metastasis include prior tumors, ill-defined borders, aggressive histologic patterns, and perineural invasion. Mohs micrographic surgery has the lowest recurrence rate among treatments but is best considered for large, high-risk tumors or tumors in sensitive anatomic locations. Smaller, lower-risk tumors are treated with surgical excision, electrodesiccation and curettage, or cryotherapy. Topical imiquimod and fluorouracil are also treatment options for superficial basal cell carcinoma and squamous cell carcinoma in situ. There are no clear guidelines for follow up after an index keratinocyte carcinoma, but monitoring for recurrence is important because the five-year risk of subsequent skin cancer is 41%. After more than one diagnosis, the five-year risk increases to 82%. Copyright (C) 2020 American Academy of Family Physicians.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 50 条
  • [21] Shingles and pneumonia and risk of cutaneous basal and squamous cell carcinoma
    Drucker, Aaron M.
    Li, Wen-Qing
    Cho, Eunyoung
    Li, Tricia
    Besdine, Richard
    Qureshi, Abrar A.
    Linos, Eleni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) : 492 - 495
  • [22] Skin Architecture, Kidney Transplantation, and Their Relationship to Basal and Squamous Cell Carcinomas
    Capasso, Anna
    Bilancio, Giancarlo
    Lee, Michael W.
    Palladino, Giuseppe
    Pollastro, Rosa Maria
    Simeoni, Mariadelina
    Secondulfo, Carmine
    Ronchi, Andrea
    Caputo, Alessandro
    Franco, Renato
    Zeppa, Pio
    Capasso, Giovambattista
    Viggiano, Davide
    ANTICANCER RESEARCH, 2020, 40 (07) : 4017 - 4022
  • [23] Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients
    Cheng, Joyce Y.
    Li, Fang-Yong
    Ko, Christine J.
    Colegio, Oscar R.
    JAMA DERMATOLOGY, 2018, 154 (01) : 60 - 66
  • [24] Treatment of basal cell carcinoma
    Wetzig, Tino
    Maschke, Jan
    Kendler, Michael
    Simon, Jan C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (12): : 1075 - 1083
  • [25] Dermatologic radiotherapy in the treatment of extensive basal cell carcinomas: a retrospective study
    Piccinno, R.
    Benardon, S.
    Gaiani, F. M.
    Rozza, M.
    Caccialanza, M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (05) : 426 - 430
  • [26] Premalignant lesions, basal cell carcinoma and melanoma in patients with cutaneous squamous cell carcinoma
    Korhonen, Niina
    Ylitalo, Leea
    Luukkaala, Tiina
    Itkonen, Julius
    Haihala, Henni
    Jernman, Juha
    Snellman, Erna
    Palve, Johanna
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2021, 313 (10) : 879 - 884
  • [27] Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor
    Skvara, Hans
    Kalthoff, Frank
    Meingassner, Josef G.
    Wolff-Winiski, Barbara
    Aschauer, Heinrich
    Kelleher, Joseph F.
    Wu, Xu
    Pan, Shifeng
    Mickel, Lesanka
    Schuster, Christopher
    Stary, Georg
    Jalili, Ahmad
    David, Olivier J.
    Emotte, Corinne
    Antunes, Ana Monica Costa
    Rose, Kristine
    Decker, Jeremy
    Carlson, Ilene
    Gardner, Humphrey
    Stuetz, Anton
    Bertolino, Arthur P.
    Stingl, Georg
    De Rie, Menno A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (08) : 1735 - 1744
  • [28] Vismodegib: a promising drug in the treatment of basal cell carcinomas
    Dirix, Luc
    Rutten, Annemie
    FUTURE ONCOLOGY, 2012, 8 (08) : 915 - 928
  • [29] Treatment Options for Basal Cell Carcinomas of the Medial Canthus
    Papadopoulou, C.
    Solbach, M. C.
    Lorenz, B.
    Luciani, F.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (01) : 38 - 43
  • [30] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma
    Chen, Tina
    Bertenthal, Daniel
    Sahay, Anju
    Sen, Saunak
    Chren, Mary-Margaret
    ARCHIVES OF DERMATOLOGY, 2007, 143 (11) : 1386 - 1392